Skip To Main Content
Jonathan Metts on Muck Rack

Jonathan Metts

Austin
As seen in: Nintendo World Report, Nature, Wiley Online Library, MDPI, Aerospace America, Radio Free Nintendo
(I'm at the other place that feels like this place but before...)
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jonathan

Contact Jonathan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Outcomes of Children With Orbital Rhabdomyosarcoma, 1991–2016: A Report From the International Soft Tissue Sarcoma Consortium (INSTRuCT)

|
By Jonathan Metts, James Anderson, Christian Vokuhl
| Wiley Online Library Verified
Conflicts of Interest James Anderson reports a relationship with Merck & Co Inc that includes employment and equity or stocks. Julie Bradley reports a relationship with Proton Collaborative Group that includes board membership. The remaining authors declare no conflicts of interest. Data Availability Statement Data are available upon request and approval by the INSTRuCT Consortium.
Open in Who Shared Issue with article?

Paediatric Therapeutic Development Workshop on rhabdomyosarcoma

|
By Joseph Baxter, Claudia Montiel Equihua, Jan J. Molenaar, Jamie M. Aye, Gianni Bisogno, Patricia Blanc, Willemijn B. Breunis, Julia C. Chisholm, Jacquelyn Crane, Sam Daems, Laura Danielson, Bram de Wilde, Adam D. Durbin Verified, Felipe Galvez-Cancino, Patrizia Gasparini, Birgit Geoerger, Simone Graham, Mark E. Hatley, Delphine Heenen, Christine M. Heske, Simone Hettmer, Peter Houghton, Pamela R Kearns, Charles Keller, Javed S. Khan, David M. Langenau, Geffen Lass, Leo Mascarenhas, Michael Meister, Jonathan Metts, Veronique Minard-Colin, Sapna Oberoi, Daniela Palacios, Abbe Pannucci, Seema Patel, Sheena M Patel, Silvia Pomella, Terry Rabbitts, Rossella Rota, Erin R Rudzinski, Beat W. Schäfer, Karin Straathof, Rajkumar Venkatramani, Marco Wachtel, Sara Wakeling, Zoe Walters, Sam Warburton, Brenda J. Weigel, Andrew Pearson, David Jenkinson Verified, Janet Shipley, Michela Casanova, Innovative Therapies, Bass Hassan, Elizabeth Hookham, Fiona Kinnis, Corinne Mary Linardic, John Jack Shern
| Nature Verified
Abstract The third in a series of Paediatric Therapeutic Development Workshops focused on rhabdomyosarcoma. Rhabdomyosarcoma is the most common soft tissue sarcoma in children, with 90% survival for those with the lowest risk disease, but just 20–30% in children with metastatic disease. An urgent unmet need exists to develop targeted therapeutics for high-risk disease and to reduce the toxicity of treatment.
Open in Who Shared Issue with article?

A Phase I Trial of Nab‐Paclitaxel in Combination With Gemcitabine for Relapsed/Refractory Pediatric Solid Tumors

|
By Jonathan Metts, Zhulin He, Rohali Keesari, Kevin Ginn
| Wiley Online Library Verified
Funding: Study funding and drug supply of nab-paclitaxel were provided by Bristol Myers Squibb as study funder and supplier of nab-paclitaxel. Correlative work was generously funded by the Scott Shockley Foundation as funder of correlative work. This work has been supported in part by the Cancer Pharmacokinetics and Pharmacodynamics Core at the H.
Open in Who Shared Issue with article?
See all 17 licensed articles (19 Total)